This study is currently recruiting participants.
Number
01-C-0038
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 18 Years Max Age: N/A
Referral Letter Required
No
Population Exclusion(s)
Children;Adults who are or may become unable to consent
Keywords
Tumor; Viruses; HIV; KSHV; AIDS; Natural History
Recruitment Keyword(s)
None
Condition(s)
HIV; Kaposi's Sarcoma; Lymphomas; Multicentric Castleman's Disease; Primary effusion lymphoma
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Supporting Site
National Cancer Institute
OBJECTIVES: Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from patients with HIV infection, KSHV infection, or with cancer.
ELIGIBILITY: Eligibility criteria include age 18 years or older and at lest one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.
DESIGN: Blood samples may be collected at the initial visit, and at follow-up visits. Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the patients. Specific risks will be described in a separate consent to be obtained at the time of the biopsy. Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators.
--Back to Top--
INCLUSION CRITERIA: -Age 18 years or older. -ECOG performance status less than or equal to 3. At least one of the following: --Exposure risk to HIV, KSHV, or HPV --HIV seropositive --KSHV seropositive --EBV seropositiv --HTLV-1 seropositive NOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if patients have previously been seropositive or have had a disease associated with KSHV (KS, primary effusion lymphoma [PEL], or KSHV-multicentric Castleman s disease), this is sufficient to meet this criterion for eligibility. -Malignancy, Castleman's disease, or skin lesions with appearance of Kaposi's sarcoma -Cervical or anal intraepithelial lesion -Ability of subject to understand and the willingness to sign a written informed consent document. Participants could have a witness signature if they are either blind or illiterate, etc. EXCLUSION CRITERIA: Inability to provide informed consent.
-Age 18 years or older.
-ECOG performance status less than or equal to 3.
At least one of the following:
--Exposure risk to HIV, KSHV, or HPV
--HIV seropositive
--KSHV seropositive
--EBV seropositiv
--HTLV-1 seropositive
NOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if patients have previously been seropositive or have had a disease associated with KSHV (KS, primary effusion lymphoma [PEL], or KSHV-multicentric Castleman s disease), this is sufficient to meet this criterion for eligibility.
-Malignancy, Castleman's disease, or skin lesions with appearance of Kaposi's sarcoma
-Cervical or anal intraepithelial lesion
-Ability of subject to understand and the willingness to sign a written informed consent document. Participants could have a witness signature if they are either blind or illiterate, etc.
EXCLUSION CRITERIA:
Inability to provide informed consent.
Principal Investigator
Referral Contact
For more information: